Proflosin

Quick links to important sections

Proflosin

Selected form

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Proflosin

Quick Facts

Property Description
Active ingredient Tamsulosin Hydrochloride
Form Oral Capsule (Modified-Release)
Pharmacological class Alpha-Adrenergic Receptor Antagonist (Alpha-1 Blocker)
Common use Symptomatic relief of functional urinary issues
Origin Synthetic substance

1. Defining Proflosin: The Pharmaceutical Entity and its Class

Proflosin is a prescription pharmaceutical preparation whose active substance is Tamsulosin Hydrochloride. This compound is classified as an Alpha-Adrenergic Receptor Antagonist, commonly known as an Alpha-1 Blocker.

The Tamsulosin Hydrochloride component is a synthetic substance, chemically derived from the sulfonamide class. Proflosin is characterized by its selective Alpha-1 blocking action, meaning it primarily targets specific receptor sites found predominantly in the smooth muscle of the lower urinary tract. This selective profile is a differentiating feature supported by pharmacological studies.

2. Form and Functional Type of the Drug

Proflosin is manufactured for administration via the oral route, typically formulated as a capsule. Crucially, it is a modified-release formulation, a key product design that ensures the Tamsulosin Hydrochloride is delivered at a controlled, sustained rate over a prolonged period.

The drug's functional type is that of a symptomatic treatment agent. Its general purpose is to provide functional relief by promoting the smooth muscle relaxation of tissues in the prostate and bladder neck, thereby reducing physical obstruction. Clinical consensus holds that Tamsulosin improves urine flow parameters in men experiencing obstructive urinary symptoms. The modified-release form is essential for supporting convenient once-daily administration, making it a reliable remedy for persistent urinary discomfort.

Regulatory References

  1. Tamsulosin Drug Information

What side effects are possible with Proflosin?

Possible Side Effects and Safety Information

The safety profile of Proflosin (tamsulosin hydrochloride), an Alpha-1 Blocker, is documented in official regulatory labels and categorized by frequency and the body system affected.

Official Adverse Reactions and Frequency

The officially listed adverse reactions are grouped based on the frequency observed in clinical studies and post-marketing data:

Frequency Category System Organ Class (SOC) Documented Adverse Reactions
Common (Up to 1 in 10) Nervous System, Reproductive System Dizziness, Headache, Ejaculation disorders (e.g., retrograde ejaculation)
Uncommon (Up to 1 in 100) Vascular, Cardiac, Gastrointestinal, Skin Orthostatic hypotension, Palpitations, Nausea, Diarrhoea, Rash
Rare (Up to 1 in 1,000) General Disorders, Skin Angioedema (swelling of face, lips, or throat)
Very Rare (Up to 1 in 10,000) Reproductive System, Skin Priapism (persistent, painful erection), Stevens-Johnson syndrome

Safety Constraints and Special Considerations

The risk of orthostatic hypotension is specifically noted in regulatory documents as occurring more frequently at the initiation of treatment.

Certain reactions are classified as serious, including Angioedema, Priapism, and Stevens-Johnson syndrome. Additionally, the ophthalmological complication Intraoperative Floppy Iris Syndrome (IFIS) has been reported during cataract and glaucoma surgery in patients taking alpha-1 blockers, which is noted in the official prescribing information.

Regarding special populations, the safety data for Proflosin is officially not studied in patients with severe hepatic impairment or end-stage renal disease. Caution is also noted concerning individuals with a known sulfa allergy, as tamsulosin is a sulfonamide derivative.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documentation for Proflosin (Tamsulosin Hydrochloride) addresses overdosage primarily through the risk of exaggerated pharmacological effects.

Documented Overdose Manifestations

The most significant and documented clinical manifestation is the occurrence of acute hypotension, which is classified as a potentially severe hypotensive effect. Symptoms associated with overdosage may include generalized dizziness and a risk of syncope (fainting). Gastrointestinal effects such as vomiting and diarrhea have also been reported in documented cases.

Required Emergency Actions

Regulatory authorities mandate that individuals must seek emergency medical attention immediately if an overdose is suspected or confirmed. Urgent assistance, such as contacting emergency services or a Poison Control Center, is required for the most severe presentations, including signs of collapse, difficulty breathing, or inability to be awakened.

Official Management Profile

Treatment for Proflosin overdosage is strictly symptomatic and supportive. No specific chemical antidote is known to exist. Regulatory guidance outlines procedures such as placing the patient in a supine position to aid blood pressure restoration, followed by the use of volume expanders and vasopressors if stability is not achieved. Measures to impede further absorption, including gastric lavage or the administration of activated charcoal and an osmotic laxative, are documented procedures for cases involving large quantities. Monitoring of renal function is also required.

Therapeutic Uses of Proflosin

What Proflosin Treats: Main Uses and Benefits

Proflosin, which contains the active substance tamsulosin hydrochloride, is commonly used across conditions presenting with acute episodes. This is particularly relevant in conditions characterized by periods of heightened symptoms, such as lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH), commonly known as an enlarged prostate. The medication is utilized in clinical contexts involving heightened functional burden on the urinary system.

The therapeutic domain is applied in addressing symptom clusters that may become intense or disruptive. The medication may assist with managing symptoms that interfere with daily functioning and those symptoms linked to organ-specific functional stress. It is commonly used when symptoms become more noticeable and supportive relief is needed. The medication assists with maintaining functional stability and contributes to improved comfort during periods of heightened symptoms.

The medication is applied in addressing symptom clusters that may become intense or disruptive and supports general well-being during symptomatic phases.

Quick Fact: Relevant for Easing Symptoms that Interfere with Daily Functioning

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Proflosin?

Proflosin (Tamsulosin Hydrochloride) eligibility is defined by regulatory bodies based on age, gender, and existing medical status. The medication is officially indicated only for use in adult males for the management of symptoms related to benign prostatic hyperplasia (BPH).


Contraindications

Proflosin is contraindicated and must not be used by patients with a known hypersensitivity to tamsulosin or its components, or by individuals with a history of orthostatic hypotension (low blood pressure upon standing).


Age and Gender Restrictions

The medicine is not indicated for use in women or the pediatric population (children and adolescents). While use is established in older adults, some geriatric patients may exhibit greater sensitivity.


Conditional Use and Unestablished Groups

Use is restricted in certain cases: the initiation of therapy is not recommended for patients scheduled for cataract or glaucoma surgery. Furthermore, the medication has not been studied in populations with severe hepatic impairment or those with End Stage Renal Disease.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Proflosin (Tamsulosin Hydrochloride) has officially documented interaction patterns that establish constraints on co-administration with specific medicinal products, primarily involving pharmacokinetic and pharmacodynamic effects.

Contraindicated Combinations

Co-administration with other alpha-adrenergic blocking agents is prohibited due to the risk of symptomatic hypotension from an additive pharmacodynamic effect. The combination with Strong Inhibitors of CYP3A4 (such as Ketoconazole) is also contraindicated, as this significantly increases the systemic exposure of Proflosin.

Pharmacokinetic and Pharmacodynamic Effects

Proflosin is metabolized by CYP3A4 and CYP2D6 enzymes. Strong inhibitors of these pathways, like Ketoconazole and Paroxetine, are documented to increase Proflosin's plasma levels. Certain moderate CYP inhibitors (e.g., Erythromycin, Terbinafine) require caution when co-administered. The drug Cimetidine is documented to increase Proflosin exposure by decreasing its systemic clearance.

Caution is advised when Proflosin is combined with Phosphodiesterase-5 (PDE-5) Inhibitors (e.g., Sildenafil), as this interaction carries a potential for additive vasodilation and hypotension.

Administration Requirements

Due to the effect of food on the absorption of the modified-release capsule, official regulatory documentation requires the medicine to be administered approximately one-half hour following the same meal each day to ensure consistent drug exposure.

Mechanism of Action

Proflosin acts as an inhibitor targeting the sodium-glucose co-transporter system (SGLT), exhibiting activity at both SGLT1 and SGLT2 isoforms. Its molecular structure permits competitive interaction at the active site of these transporter proteins, which are primarily expressed on the apical membrane of the small intestinal epithelium (SGLT1) and the renal proximal convoluted tubule (SGLT2).

Inhibition of SGLT2 in the kidney reduces the maximal transport capacity for glucose reabsorption. This reduction decreases the flux of glucose from the tubular lumen back into the systemic circulation. Inhibition of SGLT1 in the intestine attenuates the active uptake of glucose from the gut lumen into enterocytes. The resulting molecular consequence is an increased luminal concentration of glucose within the renal tubules and the intestinal tract. This alteration in transmembrane transport generates a system-level physiological consequence of modified glucose handling, characterized by an enhanced excretion of glucose via the urine and a reduced rate of intestinal glucose absorption.

Dosage and Administration Information

How to use Proflosin

Proflosin, containing Tamsulosin Hydrochloride, is an oral medication formulated as a modified-release capsule. The drug's usage protocol is standardized to ensure the intended prolonged release of the active substance, which dictates the specific manner in which the medicine must be taken.

Administration Guidelines

The standard regimen involves once-daily dosing. The initial labeled dose is established at 0.4 mg. This may be increased to a maximum of 0.8 mg once daily for patients who do not achieve an adequate response after two to four weeks of treatment at the initial dose.

Instruction Official Requirement
Timing Must be taken approximately one-half hour following the same meal each day.
Handling The capsule must be swallowed whole and must not be crushed, chewed, or opened.
Dose Restart If treatment is interrupted for several days, administration must restart at the lower 0.4 mg dose.
Pediatric Use The medication is not indicated for use in the pediatric population.

This protocol links administration to a specific time in relation to food and emphasizes maintaining the capsule's physical structure to guarantee consistent delivery of the modified-release formulation.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Proflosin

1. Evidence for Lower Urinary Tract Symptoms (LUTS) in BPH

Research for Proflosin (Tamsulosin Hydrochloride) has primarily focused on studies exploring how symptoms change over time in men diagnosed with Benign Prostatic Hyperplasia (BPH). These conditions characterized by fluctuating or episodic manifestations were primarily studied through numerous, short-term Randomized Controlled Trials (RCTs). Researchers in these trials monitored subjective symptom scales (patient-reported outcomes describing perceived discomfort) and tracked functional parameters such as maximum urinary flow rate.

The findings describe patterns observed in the studies where groups assigned to Proflosin were compared to groups assigned to an inactive placebo (control group). Research reports the changes measured in the patient-reported symptom scores during the study period. Data indicate patterns related to how symptoms evolved in the observed populations in short-term research, typically over eight to thirteen weeks. Systematic Reviews and Meta-Analyses compiled results from multiple RCTs, contributing to the broader evidence landscape related to symptom patterns.

2. Research into Symptoms Associated with Ureteral Stents

Proflosin was evaluated in studies focusing on another clinical situation: symptoms related to the presence of a ureteral stent following certain surgical procedures. This research explored short-term symptom changes in adult patients (men and women) who had a temporary stent placed. Studies monitored stent-specific symptom scores, which are outcomes related to physical discomfort and general urinary symptoms.

3. Understanding Long-Term Study Data and Durability

While the core efficacy trials for LUTS/BPH were short-term, Proflosin was observed in multi-year Long-Term Extension Studies. These studies explored the sustained use of Proflosin, with some cohorts being monitored for up to four to six years. Research describes the sustained observation of symptom measurements and functional parameters in these cohorts. Long-term effects are not fully established because the data collection is subject to patients withdrawing or being lost to follow-up over time, meaning the results apply only to the observed populations.

4. Key Research Gaps and Remaining Uncertainties

The official research record highlights several areas where more information is needed. Follow-up durations were limited for the secondary indication (ureteral stents), where data are still emerging. Population diversity in the foundational BPH studies was modest, meaning data for certain groups remain insufficient regarding long-term use. Research does not determine whether an individual will respond similarly to the group patterns observed in trials, emphasizing that findings describe group patterns, not personal outcomes.

Frequently Asked Questions (FAQ)

Common questions about Proflosin (FAQ)

Q: Is Proflosin also approved for treating high blood pressure?

Official product information states that Proflosin is specifically indicated for the management of symptoms related to an enlarged prostate, known as Benign Prostatic Hyperplasia (BPH). The drug is not approved or intended for treating high blood pressure (hypertension).

Q: Does Proflosin physically shrink the size of the prostate gland?

No, Proflosin does not physically reduce the size of the prostate gland. Its mechanism is to relax the smooth muscles in the prostate and bladder neck, which helps improve urine flow. Official information notes that the prostate may continue to enlarge even while taking this medication.

Q: Is there a difference in how Proflosin works compared to other common BPH medications?

Proflosin is classified as a selective alpha-1a adrenergic antagonist, often referred to as an alpha-blocker. This means it primarily targets the receptors that control muscle relaxation in the lower urinary tract. This selective action is intended to primarily benefit urinary symptoms.

Q: How long is Proflosin typically intended to be taken for?

For the symptomatic relief of BPH, official guidance indicates that if Proflosin is effective, treatment duration is often guided by long-term efficacy studies. For other conditions where the active ingredient may be used, the treatment duration is typically shorter and is determined by a healthcare provider.

Q: Is Proflosin generally considered a long-term treatment?

Yes, for men seeking relief from symptoms of an enlarged prostate, Proflosin is a medication that may be continued for a long period of time. Research evidence reports that the positive effects on symptoms have been maintained during long-term therapy. Continued use requires periodic evaluation.

Q: Is Proflosin usually prescribed alone or as part of combination therapy?

Proflosin is available as a single-ingredient prescription and can be taken alone. However, research indicates that fixed-dose combination capsules containing its active ingredient and other medications have been studied for co-administration when treating BPH symptoms alongside other conditions.

Q: What is the recommended action if a dose of Proflosin is missed?

Official guidance advises taking a dose as soon as possible if remembered on the same day. If not remembered until the next day, the missed dose should be skipped, and the subsequent dose taken at the usual time. Taking a double dose to compensate for a missed dose is not recommended by official guidance.

Q: Can Proflosin have an effect on sexual drive or the ability to get or maintain an erection?

Regulatory documents list ejaculation disorders, such as a decrease in semen volume, as a common side effect. Regarding other sexual function effects, the rare but serious side effect of priapism (a prolonged and sometimes painful erection) has been reported with this class of drug.

Q: Is it common to experience flu-like symptoms or a cold shortly after starting Proflosin?

Flu-like symptoms have been noted in post-marketing safety reports for this class of medication. While the frequency is not commonly defined in primary regulatory sources, these symptoms have been noted as a potential reaction.

Q: Does Proflosin have any known effects on the nasal passages, such as causing a runny or stuffy nose?

Official prescribing information indicates that effects on the nasal passages are possible. A runny nose is listed as a common adverse reaction, and reports of nasal stuffiness have also been documented.

Q: Can taking Proflosin be associated with back or joint pain?

Yes, the oral dosage form of the medication has been associated with reports of lower back or side pain, which is noted as a more common side effect. Joint or muscle pain has also been reported in clinical contexts.

Q: Are there any known cognitive side effects, such as memory issues, linked to Proflosin?

Research has examined the potential impact of this drug on cognitive function due to the presence of targeted receptors in the brain. However, some studies indicate the medication is generally not associated with the worsening of cognitive decline in observed patient groups.

Q: Do the initial side effects of Proflosin typically lessen or go away after continued use?

Official documents contain an instruction to notify a healthcare provider about any side effect that persists. This instruction implies that some common or initial side effects may subside or decrease with continued use of the medication.

Q: What is the general guidance on consuming alcohol while taking Proflosin?

Combining alcohol with Proflosin can increase the risk of experiencing lowered blood pressure. This effect may increase the chance of feeling dizzy, lightheaded, or potentially fainting, especially when changing positions (like standing up).

Q: Are there any specific over-the-counter medicines or common supplements that are known to interact with Proflosin?

Official drug labels document interactions with specific over-the-counter medications. For example, the pain reliever Diclofenac should not be used when taking Proflosin. It is important for patients to ensure their healthcare provider is aware of all prescription and non-prescription products being used.

Q: Does Proflosin interact with common prescription medications for high blood pressure?

Yes, the official information indicates that Proflosin may interact with some prescription medications used to treat high blood pressure. This combination could lead to an additive blood pressure-lowering effect.

Q: Does Proflosin interact with herbal supplements commonly marketed for prostate health?

Regulatory sources state that there is insufficient information available to definitively determine if Proflosin is safe to take alongside complementary medicines or herbal remedies, including those marketed for prostate health.

Q: Is it typically necessary for a patient to temporarily stop Proflosin before certain non-emergency medical procedures?

Official information emphasizes informing the surgeon or doctor about the use of Proflosin before any surgical procedure, including dental surgery. This warning is particularly noted before eye surgeries, such as cataract or glaucoma procedures.

Q: Can Proflosin be safely used alongside medication prescribed for an overactive bladder?

The potential for interaction between Tamsulosin, the active ingredient in Proflosin, and certain medications prescribed for overactive bladder (OAB) has been examined in clinical studies. It is important to ensure the healthcare provider is aware of all medications being taken.

Q: Does Proflosin interact with pain relievers?

Official documents provide specific guidance on pain relievers. The use of the pain reliever Diclofenac is documented in official sources as requiring caution or avoidance with Proflosin. However, the use of common pain relievers like Paracetamol and Ibuprofen is generally acceptable.

Q: Is special monitoring by a healthcare provider required when Proflosin is taken with other prescription drugs?

Special monitoring may be necessary when Proflosin is taken with other prescription drugs, particularly those that affect its breakdown in the body or those that can lower blood pressure. In these cases, a healthcare provider may need to check blood pressure or laboratory values more often.

Q: Are there different considerations for using Proflosin in elderly patients?

Studies conducted to date have not found unique problems specifically related to older patients that would limit the drug's effectiveness. Therefore, Tamsulosin is generally utilized for BPH in the elderly population, as studies have not found age-specific limitations.

Q: Is Proflosin ever prescribed or studied for use in female patients?

Proflosin is not officially indicated or approved for use in women, as it is prescribed for male BPH symptoms. However, Tamsulosin, the active ingredient, has been evaluated in research contexts for other conditions, such as the expulsion of kidney stones, which included female patients.

Q: Is Proflosin use linked to any changes in Prostate-Specific Antigen (PSA) test results?

Official guidance recommends that Prostate-Specific Antigen (PSA) testing be performed before starting treatment and at regular intervals afterwards. Research evidence generally indicates that Proflosin does not significantly affect PSA levels.

Q: What does the research evidence say about the long-term effectiveness of Proflosin?

Research evidence indicates that the positive effects of Proflosin on both urinary storage and voiding symptoms have been sustained during long-term therapy. Studies suggest that continued use is associated with a delay in the need for related surgery or catheterization in the patient populations observed.

Q: Does Proflosin have any warnings related to pre-existing heart conditions?

Post-marketing adverse event reports for this medication include instances of fast, pounding, or irregular heartbeat. Although the frequency is not known, these effects are documented in post-marketing reports.

Q: Is it true that Proflosin does not require blood pressure monitoring or dose titration?

Official documentation indicates that the dose may be increased after a few weeks if necessary, meaning dose titration is possible. The known risk of orthostatic hypotension (low blood pressure upon standing) suggests that monitoring may be necessary during treatment initiation and dose changes.

How should Proflosin be stored and disposed of?

How to Store and Dispose of Proflosin

Proflosin (Tamsulosin Hydrochloride) must be stored under specific conditions to maintain its effectiveness, as documented in official regulatory labeling.

Storage Requirements

Store the capsules at controlled room temperature, typically 20 C to 25 C (68 F to 77 F), with permitted excursions up to 30 C. The product must be kept away from excess heat and moisture. Always store Proflosin in the original container, ensuring it is tightly closed. For safety, the medication must be kept out of the sight and reach of children.

Disposal Instructions

Do not flush Proflosin down the toilet or pour it down a drain. Unused or expired medication should be disposed of via a formal drug take-back program. If a program is unavailable, mix the capsules with an unappealing substance, seal them in a plastic bag or container, and place them in the household trash, following local regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Proflosin found in:

A-Z Index: